Oncology

Loew
Biotech

Ipsen inks $1.7B deal to buy Kartos for potential Jakafi add-on

Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
James Waldron Jun 29, 2026 8:03am
Cancer mutation precision medicine oncology targeted

BIO 2026: How a gut feeling transformed cancer treatment forever

Jun 25, 2026 9:23am
Robotic hand stacking coins

With $15M, BI becomes latest to buy into Immunai’s AI platform

Jun 25, 2026 9:00am
Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation

Novartis pays Antares $105M to tackle undruggable cancer targets

Jun 24, 2026 9:13am
Pharma money pharma money pharma profits Big Pharma sales drug sales
Favicon Fierce Pharma

Obesity meds, China drive $2T in projected 2032 drug sales: report

Jun 23, 2026 9:00am
forest

Treeline sees path to public markets via reverse merger

Jun 8, 2026 10:37am
More News

Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Jun 3, 2026 9:48am

ASCO: Cardiff posts updated colorectal data before pivotal push

Jun 2, 2026 9:06am

ASCO: Takeda touts ‘tremendous potential’ of Innovent bispecific

Jun 2, 2026 4:30am

Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?

May 22, 2026 8:28am